HOME >> MEDICINE >> NEWS
Serendipity versus planning - cancer drugs of the future?

Delegates at the European Breast Cancer Conference (EBCC-5) were given two examples of promising new drugs to watch in the future - raloxifene and lapatinib.

New anticancer drugs are usually developed specially for the job, but occasionally they are borrowed from another field of medicine, and applied speculatively in cancer. Tamoxifen was designed as an anti-oestrogen, based on the observation that at least a third of breast cancers depend on female sex hormones such as oestrogen for survival. Tamoxifen has shown to be an exceptionally effective molecule in cancer treatment; It was never planned to be a preventive agent, but so it has proved to be! It is now licensed to be used to prevent breast cancer in certain women at high risk of the disease.

Contrast this with raloxifene, a drug first developed to treat osteoporosis in women. A selective benzothiophene oestrogen receptor modulator (SERM), raloxifene binds to oestrogen receptors as a mixed oestrogen and anti-oestrogen effect. It functions as an oestrogen sometimes (in bones and on lipid metabolism) and as an anti-oestrogen in other target tissues (endometrium and breast). So, it has the potential for producing some of oestrogen's beneficial effects without producing its adverse effects. In a trial of its use in osteoporosis, it appeared to have another completely different effect, namely prevention of new hormone dependant breast cancers.

Results from the MORE (The Multiple Outcomes of Raloxifene Evaluation) study of 7,705 women that were randomised to raloxifene or placebo demonstrated that among postmenopausal women with osteoporosis, the risk of invasive breast cancer was decreased by 76% during three years of treatment with raloxifene.

Stronger evidence on the safety and efficacy of raloxifene is awaited from the STAR Trial. This trial includes almost 20,000 postmenopausal women in the US who are at increased risk of breast cancer to determine whether raloxifene is as e
'"/>

Contact: EBCC-5 Press Office
stephanie.makin@toniclc.com
33-493-928-402
Federation of European Cancer Societies
24-Mar-2006


Page: 1 2 3

Related medicine news :

1. Experts predict Tamiflu could halve the pandemic influenza death toll versus no intervention
2. Quality versus quantity -- transforming kidney transplant policy
3. Fixed versus growth intelligence mindsets: Its all in your head, Dweck says
4. Mechanism of black cohosh versus hot flashes revealed
5. IMRT versus 3D CRT for prostate cancer, new long-term data assesses side effects
6. Adolescent condom use with casual versus main partners
7. Study shows rituximab effective in treating chronic graft-versus-host disease
8. Gap widens between optimal versus actual cholesterol levels
9. CT colonography versus colonoscopy for colorectal cancer
10. The economics of prescription drugs versus OTC
11. Inverse planning system improves brachytherapy treatment for prostate and other cancers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Serendipity versus planning cancer drugs the future

(Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
(Date:10/20/2014)... 2014 Based on a proprietary ... imaging assays capable of determining DNA sequence, location ... these three dimensions of high-resolution data, dGH assays ... widest range of disease-causing genetic rearrangements, including chromosomal ... genomic tools, including today’s advanced sequencing technologies. , ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center for ... ROI on membership dues at 12.5. In other words, for ... value to member hospitals. The calculation used to determine member ... , “This is the first time we’ve actually been able ... is really sound,” said Bill Ryan , president and ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently ... are the best Dedicated Server Hosting suppliers. Their ... to buy high quality hosting and save money ... of Top10BestSEOHosting.com says, “We believe that iPage and ... A lot of the global clients enjoy using ...
Breaking Medicine News(10 mins):Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2
(Date:10/20/2014)... ALBANY, N.Y. , Oct. 20, 2014 ... pharmaceutical outsourcing facility in Albany, NY ... and trials. The company meets and/or exceeds the FDA ... 210 and 21 CFR Part 211. ... provide the highest levels of quality assurance and quality ...
(Date:10/20/2014)... and RALEIGH, N.C., Oct. 20, 2014  BioPontis Alliance ... (HNF), both philanthropies, announced today the creation of ... the treatment of the rare disease known as ... announced its alliance model earlier this month. Today,s ... of a collaborative model where researchers and all ...
(Date:10/19/2014)... 19, 2014  Henry Schein, Inc. (NASDAQ: ... products and services to office-based dental, animal health and ... Iwase Dental Supply, Inc., a leading full-service provider of ... Henry Schein,s entrance into Japan , ... increases to 28 the number of countries in which ...
Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5
Cached News: